A Phase 3 Randomized Double-blind Multicenter Study of TSR-042 plus Carboplatin-Paclitaxel versus Placebo plus Carboplatin-Paclitaxel in Patients with Recurrent or Primary Advanced Endometrial Cancer

Brief description of study

You are being asked to participate in this research study because you have endometrial cancer. This study is being done to find out if an investigational drug called dostarlimab (also known as TSR-042) an immunotherapy drug in combination with chemotherapy (carboplatin and paclitaxel), can help delay worsening of cancer among patients.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.